Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera

Press/Media

Period15 Mar 2023

Media coverage

1

Media coverage

  • TitleProtagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera
    Media name/outletFSCwire
    Country/TerritoryCanada
    Date15/03/23
    PersonsRonald Hoffman
View all 1
View less